These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 7606734

  • 1. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors.
    Stein R, Goldenberg DM, Thorpe SR, Basu A, Mattes MJ.
    Cancer Res; 1995 Jul 15; 55(14):3132-9. PubMed ID: 7606734
    [Abstract] [Full Text] [Related]

  • 2. Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides.
    Stein R, Govindan SV, Mattes MJ, Shih LB, Griffiths GL, Hansen HJ, Goldenberg DM.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3079s-3087s. PubMed ID: 10541347
    [Abstract] [Full Text] [Related]

  • 3. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung.
    Stein R, Goldenberg DM, Thorpe SR, Mattes MJ.
    J Nucl Med; 1997 Mar 15; 38(3):391-5. PubMed ID: 9074526
    [Abstract] [Full Text] [Related]

  • 4. Improved iodine radiolabels for monoclonal antibody therapy.
    Stein R, Govindan SV, Mattes MJ, Chen S, Reed L, Newsome G, McBride BJ, Griffiths GL, Hansen HJ, Goldenberg DM.
    Cancer Res; 2003 Jan 01; 63(1):111-8. PubMed ID: 12517786
    [Abstract] [Full Text] [Related]

  • 5. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC.
    J Nucl Med; 2004 Feb 01; 45(2):327-37. PubMed ID: 14960657
    [Abstract] [Full Text] [Related]

  • 6. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer.
    Shih LB, Xuan H, Aninipot R, Stein R, Goldenberg DM.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5857s-5863s. PubMed ID: 7493360
    [Abstract] [Full Text] [Related]

  • 7. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel.
    Govindan SV, Stein R, Qu Z, Chen S, Andrews P, Ma H, Hansen HJ, Griffiths GL, Horak ID, Goldenberg DM.
    Breast Cancer Res Treat; 2004 Mar 01; 84(2):173-82. PubMed ID: 14999147
    [Abstract] [Full Text] [Related]

  • 8. Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts.
    Stein R, Blumenthal R, Sharkey RM, Goldenberg DM.
    Cancer; 1994 Feb 01; 73(3 Suppl):816-23. PubMed ID: 8306265
    [Abstract] [Full Text] [Related]

  • 9. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
    Govindan SV, Shih LB, Goldenberg DM, Sharkey RM, Karacay H, Donnelly JE, Losman MJ, Hansen HJ, Griffiths GL.
    Bioconjug Chem; 1998 Feb 01; 9(6):773-82. PubMed ID: 9815172
    [Abstract] [Full Text] [Related]

  • 10. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
    Pavlinkova G, Booth BJ, Batra SK, Colcher D.
    Clin Cancer Res; 1999 Sep 01; 5(9):2613-9. PubMed ID: 10499640
    [Abstract] [Full Text] [Related]

  • 11. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts.
    Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegel JA, Goldenberg DM.
    Cancer Res; 1990 Apr 15; 50(8):2330-6. PubMed ID: 2180566
    [Abstract] [Full Text] [Related]

  • 12. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
    Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, Hansen HJ, Blumenthal RD, Dunn RM, Juweid ME, Goldenberg DM.
    Cancer Immunol Immunother; 1997 May 15; 44(3):179-88. PubMed ID: 9191878
    [Abstract] [Full Text] [Related]

  • 13. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

  • 14. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody.
    Stein R, Govindan SV, Hayes M, Griffiths GL, Hansen HJ, Horak ID, Goldenberg DM.
    Clin Cancer Res; 2005 Apr 01; 11(7):2727-34. PubMed ID: 15814655
    [Abstract] [Full Text] [Related]

  • 15. Labeling of monoclonal antibodies with diethylenetriaminepentaacetic acid-appended radioiodinated peptides containing D-amino acids.
    Govindan SV, Mattes MJ, Stein R, McBride BJ, Karacay H, Goldenberg DM, Hansen HJ, Griffiths GL.
    Bioconjug Chem; 1999 Apr 01; 10(2):231-40. PubMed ID: 10077472
    [Abstract] [Full Text] [Related]

  • 16. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
    van Schaijk FG, Broekema M, Oosterwijk E, van Eerd JE, McBride BJ, Goldenberg DM, Corstens FH, Boerman OC.
    J Nucl Med; 2005 Jun 01; 46(6):1016-22. PubMed ID: 15937314
    [Abstract] [Full Text] [Related]

  • 17. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ, Rogers BE, Khazaeli MB, Mayo MS, Milenic DE, Kashmiri SV, Anderson CJ, Chappell LL, Brechbiel MW, Curiel DT.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [Abstract] [Full Text] [Related]

  • 18. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.
    Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC, Moscatello DK, Wong AJ, Bigner DD, Zalutsky MR.
    Cancer Res; 1995 Oct 01; 55(19):4375-82. PubMed ID: 7671250
    [Abstract] [Full Text] [Related]

  • 19. Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts.
    Roselli M, Schlom J, Gansow OA, Raubitschek A, Mirzadeh S, Brechbiel MW, Colcher D.
    J Nucl Med; 1989 May 01; 30(5):672-82. PubMed ID: 2785585
    [Abstract] [Full Text] [Related]

  • 20. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft.
    Stein R, Chen S, Haim S, Goldenberg DM.
    Cancer; 1997 Dec 15; 80(12 Suppl):2636-41. PubMed ID: 9406718
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.